Scott-Edil was envisioned by our mentor Mr. Balram Kishan Aggarwal, in the late 80s. It is one of India's fastest growing pharmaceutical company engaged in developing, manufacturing and distributing generic pharmaceutical products in India and world over in a variety of forms including syrups, capsules, ointments, oral liquids, tablets, external preparations, dry powder injections and liquid injections. Starting from a small chemist shop in Kurali, Punjab it grew to become what it is today. A company with 600+ employees, 3 manufacturing plants and large global presence.
The Company commenced business by manufacturing injectable for veterinary use. The firm received its license to manufacture human medicines on 31st August, 1995, which kick-started the company’s operations.
The next few years were of vigorous growth for Scott-Edil with the acquisition of GCM laboratories in January’97 and a contract manufacturing tie-up with Ind-Swift Laboratories in 2000.
Scott-Edil Pharmacia Pvt. Ltd. (SEPL) was born in 2002 along with a plan to start a new Skin Preparation Unit. The company’s forward looking visionaries established their presence in Himachal Pradesh in 2003, shortly after which, the state became a tax free zone.
As the production took off in 2005, SEPL built its portfolio by collaborating with pharma giants like Piramal, German Remedies, Lupin, Cadila, etc. While the plant had three segregated streams manufacturing generals, beta lactams and cephalosporin, the management felt the need to separate these lines to lay a steadier foundation. In 2009, a decision was taken to start a dedicated Cephalosporin facility and a high quality, macofar dry powder equipment was installed for washing, sterilization, filling and sealing.
This operation was driven under SEARLE’s name- Scott Edil Advanced Research Laboratories and Education Ltd. SEARLE is designed as one of its kind, state of the art facilities and is one of the largest facilities for cephalosporin in the world.
SEPL gained access to a larger horizon with the first WHO-GMP certification in 2008 and a WHO-GMP certification for SEARLE in 2012. In 2016, a dedicated unit for Beta Lactam was started by the Scott-Edil group.
In 2017 an opportunity to acquire Alembic Pharma’s Baddi facility came along for SEPL. This facility was spread over 5 acres (1, 60,000 sq ft covered area) and has one of the largest liquid manufacturing capacities in the country (with 3 different lines of capacities- 16000 lts, 4000 lts and 1000 lts). It became SEPL’s doorway to over 25 countries, post approvals, like Ukraine, Malaysia, Kenya, and Tanzania.
Today, we are moving onward and upward by focusing on a purposeful & differentiated product portfolio comprising of complex generics & specialty products. As we continue the journey started in 1988, we are moving towards accessible, affordable and high quality medicine for all.
Vaishali Aggarwal (Technical Director)
She heads the technical functions and is primarily responsible for regulatory affairs and international business. With her domain expertise and skills, she has lead the company’s exports across many emerging markets.
Akhilesh Kumar (Chief Financial Officer)
He is the Chief Financial Officer and drives the company’s compliances across financial, secretarial, banking, foreign trade and taxation domains. At Scott-Edil, he is also instrumental in maintaining the company's fiscal discipline. He is an MBA in Finance and has over 20 years of experience.